Pharmacokinetic crossover trials on GelShield Extended-Release Metformin gut tolerability, topical Diclofenac patch RCTs for targeted joint relief without GI bleeding, and Phase 3 biologic clearance trials in psoriasis and autoimmune disease. Explore 546 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
The drug has demonstrated a favorable safety profile for use in outpatient practice.
The differences found between acitretin and etretinate may be related to higher maximum plasma concentrations of acitretin.
SBRT failed to demonstrate improved CR rates after 1 month.
Apremilast-treated patients with baseline ModDA had higher probability of achieving cDAPSA treatment targets than patients with HDA.
Both devices provide a safe and effective option for patients to self-administer bimekizumab.
Twice-daily administration of bilayer tramadol tablets was as effective as four-times-daily administration of IR capsules regarding the improvement in pain VAS, with comparable safety outcomes.
Long-term tildrakizumab real-world benefits and safety were comparable between patients with and without MetS.
IXE improved the signs and symptoms of PsA in a population of difficult-to-treat patients with inadequate response to one or two TNFi.
These findings do not support the hypothesis that elevated baseline inflammatory markers predict poor response to sertraline in patients with CHD and major depression.
A short-course applied to the skin diclofenac epolamine patch, combined with rehabilitation training, effectively alleviates pain, accelerates functional recovery, and is safe for treating moderate hamstring strain, supporting...
Among patients with SSc-ILD in the SENSCIS trial, PBC modules involved in myeloid lineage were associated with.
Following discontinuation of secukinumab, a proportion of patients stayed relapse-free.
In summary, this study shows that at 1 year post injection, there was no superior orthobiologic as compared to CSI for knee wear-and-tear joint pain.
This analysis suggests that most ADRs associated with pimitespib are manageable and reversible, thus supporting its use in patients with advanced GIST.
Use of daily over weekly ratings delivered no added benefit in evaluating pain in this clinical trial.
The real-world benefits and safety of vunakizumab are not affected by different regions of China in patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups.
Guselkumab safety and real-world benefits were consistent between Hispanic and non-Hispanic populations.
In a randomized, blinded, phase III LTE study, maintenance of disease control following induction of sustained LDA/REM with baricitinib 4 mg was greater with continued 4 mg than after tapering to 2 mg.
The optimal interval of injections of depot medroxyprogesterone acetate 150 mg is every 3 months.
Caudal injection of soluble dexamethasone conferred no clinical benefit over saline placebo in patients with acute sciatica.
Intravenous hydromorphone titration for severe cancer pain was achieved more effectively with PCA than with non-PCA administration.
Serum/plasma level of type II collagen formation, PRO-C2, may be an objective indicator of a low cartilage repair endotype, displaying radiographic progression and superior response to a proanabolic drug.
Slower, flexible titration improved staying on track with medication and reduced side effects without compromising efficacy.
104 patients were randomized (mean [SD] age, 43.0 [15.4] years; 55 [52.9%] women; 4 [3.8%] Asian, 13 [12.5%] Black, and 87 [83.7%] White), including 70 with AD (41 women [58.6%]; mean [SD] ages, 41.4 [16.6] years in the...
The addition of liposomal bupivacaine to bupivacaine hydrochloride did not significantly improve opioid-sparing effect or postoperative pain compared with bupivacaine hydrochloride alone among children ≥ 6 years undergoing...
Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin single-drug treatment, it had no additional effects on insulin sensitivity and vascular inflammatory response.
Dolutegravir-based and darunavir-based regimens initiated during PHI strongly and similarly decreased the blood reservoir size.
Low-dose ILT may be associated with improved successful pregnancy and live birth rates in RPL patients. These clinical outcomes coincided with changes in purinergic signaling, inflammatory cytokines, and cellular energy status; however, formal mediation cannot be inferred from the present analysis.
Corbin Posture Scale scores decreased in both groups (p < 0.05). Pain reduction was greater in the study group (VAS: from 9.00 ± 0.67 to 2.92 ± 1.14 versus from 9.11 ± 0.64 to 7.96 ± 0.75; SF-MPQ: from 27.07 ± 4.41 to 10.07 ± 3.33 versus from 21.33 ± 2.46 to 19.37 ± 2.35; p < 0.001).
In conclusion, PBC patients with positive anti-gp210 have a worse prognosis than those with negative anti-gp210. Incorporating anti-gp210 testing into clinical practice could enhance risk stratification and guide personalized management, ultimately improving outcomes for this vulnerable population.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
